4-((6,7-二甲氧基喹啉-4-基)氧基)-2-甲基苯胺 | 228559-82-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-((6,7-二甲氧基喹啉-4-基)氧基)-2-甲基苯胺
• 英文名称: 4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methylaniline
• 英文别名: 4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methylaniline
• CAS: 228559-82-8
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: BXVUWRXAXZVIOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  487.3±45.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-三氟甲基苯磺酰氯 、 4-((6,7-二甲氧基喹啉-4-基)氧基)-2-甲基苯胺 在 吡啶 作用下， 反应 48.0h， 以32%的产率得到N-[4-(6,7-dimethoxyquinolin-4-yloxy)-2-methylphenyl]-2-trifluoromethylbenzenesulfonamide
  参考文献：
  名称：

  Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

  摘要：

  The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.

  DOI：

  10.1021/acs.jmedchem.8b00672
• 作为产物：
  描述：

  4-硝基间甲苯酚 以 氯苯 为溶剂， 生成 4-((6,7-二甲氧基喹啉-4-基)氧基)-2-甲基苯胺
  参考文献：
  名称：

  Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors

  摘要：

  (6,7-二取代喹啉-4-基氧苯基)(4-取代苯基)胺衍生物通过在人瘢痕胃癌细胞系OCUM-2MD3中进行成纤维细胞生长因子受体2（FGF-R2）的细胞自体磷酸化试验而被合成和评估。我们还进行了代谢稳定性研究，结果显示喹啉环7位的取代基会影响其生物稳定性。在本研究中，我们显著改善了双苯胺衍生物的溶解性和代谢稳定性。最具潜力的化合物15e在口服给药时表现出肿瘤体积的显著减少。 ©2003 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.bmcl.2003.12.019

文献信息

• Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
  作者：Yun Wu、Beilei Wang、Junjie Wang、Shuang Qi、Fengming Zou、Ziping Qi、Feiyang Liu、Qingwang Liu、Cheng Chen、Chen Hu、Zhenquan Hu、Aoli Wang、Li Wang、Wenchao Wang、Tao Ren、Yujiao Cai、Mingfeng Bai、Qingsong Liu、Jing Liu

  DOI：10.1021/acs.jmedchem.9b00280

  日期：2019.7.11

  Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT

  从我们先前开发的c-KIT激酶抑制剂CHMFL-KIT-8140开始，通过II型激酶抑制剂结合元件杂交设计方法，我们发现了一种新型的c-KIT激酶抑制剂化合物18（CHMFL-KIT-64），对抗c-KIT wt和具有改善的生物利用度的广谱耐药突变体。18在生化分析中显示出对c-KIT激酶和c-KIT T670I突变体的个位数nM效价，并且对近膜域中大多数功能获得性突变，ATP结合口袋中的耐药性突变均显示出极大的效价（V654A除外）和激活循环（D816V除外）。此外，18在不同物种（包括小鼠，大鼠和狗）中表现出良好的体内药代动力学（PK）特性。它还在c-KIT T670I，D820G，和Y823D突变体介导的小鼠模型以及在已知对伊马替尼具有抗性的c-KIT wt患者原代细胞中。结合广泛的临床重要c-KIT突变体的强大活性（具有良好的体内PK /药效学特性18）表明，它可能是胃肠道间质瘤的新潜在治疗候选物。
• Quinoline derivatives and quinazoline derivatives having azolyl group
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：US20030087907A1

  公开（公告）日：2003-05-08

  An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: 1 wherein X and Z represent CH or N; Y represents O or S; R 1 , R 2 , and R 3 represent H, alkoxy or the like; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, halogen, alkoxy or the like; R 9 and R 10 represent H, alkyl or the like; and R 11 represents optionally substituted azolyl.

  本发明的一个目的是提供具有强效抗肿瘤活性的化合物。根据本发明的化合物是由式（I）表示的化合物或其药学上可接受的盐或溶剂：其中X和Z表示CH或N；Y表示O或S；R1、R2和R3表示H、烷氧基或类似物；R4表示H；R5、R6、R7和R8表示H、卤素、烷氧基或类似物；R9和R10表示H、烷基或类似物；R11表示选择性取代的唑基。
• [EN] QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLINES UTILISÉS COMME INHIBITEURS DES KINASES AXL
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2009127417A1

  公开（公告）日：2009-10-22

  The present invention relates to novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.

  本发明涉及一种新型化合物，它们是AXL受体家族的受体酪氨酸激酶抑制剂。这些化合物适用于治疗或预防与AXL家族受体的受体功能亢进相关、伴随或引起的疾病。这些化合物适用于治疗增生性疾病，如癌症，特别是癌症转移。
• Quinoline and quinazoline derivatives and drugs containing the same
  申请人：——

  公开号：US20040132727A1

  公开（公告）日：2004-07-08

  There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: 1 wherein R 1 and R 2 represent hydrogen, alkyl or the like; R 3 , R 4 , R 5 and R 6 represent hydrogen, halogen, alkyl, alkoxy or the like; R 11 and R 12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R 3 , R 4 , R 5 and R 6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R 19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.

  提供了一些化合物，可用于治疗由PDGF受体自磷酸化介导的疾病，特别是可抑制新内膜形成肥大的化合物。这些化合物由式（I）或其药理学上可接受的盐或溶剂表示：1其中R1和R2表示氢，烷基或类似物；R3、R4、R5和R6表示氢，卤素，烷基，烷氧基或类似物；R11和R12表示氢，烷基，烷基羰基或类似物；而A表示公式（i）到（x）中的任意一个，但其中R3、R4、R5和R6表示氢，A表示组（v）其中u为0（零）且R19表示苯基，可选地被卤素，烷基或烷氧基取代的化合物被排除。
• Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
  申请人：Kubo Kazuo

  公开号：US20060235033A1

  公开（公告）日：2006-10-19

  An objective of the present invention is to provide compounds which have inhibitory activity against autophosphorylation of macrophage colony-stimulating factor receptors. The compounds of the present invention are represented by formula (I) and salt and solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, optionally substituted alkoxy or the like; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, halogen, alkyl, alkoxy, trifluoromethyl or the like; R 9 and R 10 represent H, alkyl or the like; and any one of R 11 and R 12 represents H with the other representing alkyl and R 13 represents an optionally substituted carbocyclic or heterocyclic ring or the like, or R 11 represents H and R 12 and R 13 combine together to form a bicyclic carbocyclic ring.

  本发明的目标是提供具有抑制巨噬细胞集落刺激因子受体自磷酸化活性的化合物。本发明的化合物由式（I）及其盐和溶剂化物表示：其中X表示CH或N；Z表示O或S；R1、R2和R3表示H、可选地取代的烷氧基或类似物；R4表示H；R5、R6、R7和R8表示H、卤素、烷基、烷氧基、三氟甲基或类似物；R9和R10表示H、烷基或类似物；R11和R12中的任意一个表示H，另一个表示烷基，R13表示可选地取代的碳环或杂环环或类似物，或R11表示H，R12和R13结合形成双环碳环。